ROCHE "se esconde" para no hablar de TAMIFLU.

The drug is a household name with millions of doses stockpiled against the threat of a potential flu pandemic and talked about alongside aspirin and penicillin as a wonder drug.

But now scientists are set to raise serious questions about the effectiveness of Tamiflu, its side-effects and the opaque way drugs get approved for widespread use on the NHS.

While the full results of the Cochrane Collaboration review into Tamiflu will not be known until tomorrow, the Department of Health is bracing itself for awkward questions about whether it rushed headlong into mass prescriptions in the wake of the 2009 swine flu outbreak.

Cochrane, a non-profit group dedicated to analyzing medical evidence, brings together the combined results of the world's best medical research studies, and are recognised as the gold standard in evidence-based health care. But during their two-year study into Tamiflu, researchers claimed they were hampered in their efforts to fully appraise the drug by the refusal of its manufacturer, Roche, to hand over all the raw data used to support their claims.

Professor Sir Iain Chalmers, a founder of the Cochrane Collaboration, told The Bureau of Investigative Journalism: "We have invested millions of pounds on stockpiling Tamiflu on the basis of a paper that presented the results of 12 trials, only two of which have been published. The investigation... shows Roche refused to provide data to evaluate these trials. Investigators got some data through the European Medicines Agency, but this doesn't answer all of the questions they have."

He added: "It is a disgrace that Roche have not provided this data." (Más)

Ver también:

New Questions Raised About Tamiflu’s Effectiveness/
NYT jan 19, 2012

Imagen tomé "prestada" de Variedades em Palavras